OCUGEN, INC. Form 8-K (Jan. 24, 2022)

Summary

Current report on Form 8-K of Ocugen, Inc., filed under Items 3.02 and 8.01, with a signature date of January 28, 2022. On January 27, 2022 the company announced that on January 24, 2022 it entered into a non-binding letter of intent with Liminal Biosciences, Inc. for the acquisition of the Liminal manufacturing site in Belleville, Ontario, for a combination of cash and warrants. As consideration for the letter of intent, the company issued warrants to purchase 2,311,404 shares of common stock at an exercise price of $3.76. The warrants vest upon closing, terminate on the tenth anniversary of issuance, and are cancellable by the company if the transactions are not consummated.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15
(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event
Reported): January 24, 2022

OCUGEN, INC.

(Exact Name of Registrant as Specified in
its Charter)

Delaware | 001-36751 | 04-3522315
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number)

263 Great Valley Parkway

Malvern , Pennsylvania 19355

( 484 ) 328-4701

(Addresses, including zip code, and telephone
numbers, including area code, of principal executive offices)

N/A

(Former Name or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):

¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting
material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
¨ | Pre–commencement
communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
¨ | Pre–commencement
communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

Securities registered pursuant to Section
12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.01 par value per share | OCGN | The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ¨

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨

Item 3.02 Unregistered Sales
of Equity Securities.

The description of the Liminal
Warrants (as defined below) contained in Item 8.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02.

Item 8.01 Other Events.

On January 27, 2022,
Ocugen, Inc. (the “Company”) announced that it had entered into a non-binding letter of intent (“LOI”) with
Liminal Biosciences, Inc. (“Liminal”) on January 24, 2022 for the acquisition of Liminal’s manufacturing site in
Belleville, Ontario, for a combination of cash and warrants to purchase the Company’s common stock, par value $0.01 per share
(“Common Stock”).

On January 24, 2022, as consideration for entering into the LOI,
the Company issued warrants (the “Liminal Warrants”) to purchase 2,311,404 shares of the Company’s Common Stock at
an exercise price of $3.76, subject to certain adjustments. The Liminal Warrants vest and become exercisable upon closing of the
transactions contemplated by the LOI and terminate on the tenth anniversary of the issuance date, unless earlier terminated in
accordance with their terms. The Liminal Warrants are cancellable by the Company in the event the transactions contemplated by the
LOI are not consummated.

The issuance of the Liminal Warrants was made pursuant to the exemption
from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

The foregoing description of the Liminal Warrants is qualified in
its entirety by reference to the full text of the Form of Liminal Warrant, a copy of which will be filed by the Company as an
exhibit to a future periodic report as required.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 28, 2022

OCUGEN, INC.
By: | /s/ Shankar Musunuri
Name: Shankar Musunuri
Title: Chief Executive Officer and Chairman

2

File and source

File

SEC_OCGN_8-K_filed2022-01-28_0001104659-22-008991.htm

Size

27,006 bytes

SHA-256

1743c0b163d5c3500254d148cb400e5db48058a4204f7f73adaa59e22fb755b1

Our copy

SEC_OCGN_8-K_filed2022-01-28_0001104659-22-008991.htm

Original

www.sec.gov